Selected research
Industry Research
Respiratory Inhalable Biologics Industry Research Report 2026
Market perspective
The global Respiratory Inhalable Biologics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Respiratory Inhalable Biologics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Respiratory Inhalable Biologics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Respiratory Inhalable Biologics include GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Chiesi, Teva and Prasco Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Respiratory Inhalable Biologics market in terms of revenue (US$ million) and, where applicable, sales volume (k units ), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units ) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Respiratory Inhalable Biologics Market by Company
GSK
AstraZeneca
Boehringer Ingelheim
Vertex
Roche
Novartis
Chiesi
Teva
Prasco Laboratories
Viatris
Amgen
Sumitomo Dainippon
Zhengdatianqing
Merck
Respiratory Inhalable Biologics Segment by Type
Protein Drugs
Peptide Drugs
Monoclonal Antibodies
Others
Respiratory Inhalable Biologics Segment by Application
Hospital
Retail Pharmacy
Others
Respiratory Inhalable Biologics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Inhalable Biologics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Inhalable Biologics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Inhalable Biologics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Respiratory Inhalable Biologics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Respiratory Inhalable Biologics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Respiratory Inhalable Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Protein Drugs
- Peptide Drugs
- Monoclonal Antibodies
- Others
Applications
- Hospital
- Retail Pharmacy
- Others
Companies covered
- GSK
- AstraZeneca
- Boehringer Ingelheim
- Vertex
- Roche
- Novartis
- Chiesi
- Teva
- Prasco Laboratories
- Viatris
- Amgen
- Sumitomo Dainippon
- Zhengdatianqing
- Merck
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Respiratory Inhalable Biologics Market Size (2021-2032)
- 2.2.2 Global Respiratory Inhalable Biologics Sales (2021-2032)
- 2.2.3 Global Respiratory Inhalable Biologics Market Average Price (2021-2032)
- 2.3 Respiratory Inhalable Biologics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Protein Drugs
- 2.3.3 Peptide Drugs
- 2.3.4 Monoclonal Antibodies
- 2.3.5 Others
- 2.4 Respiratory Inhalable Biologics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Retail Pharmacy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Respiratory Inhalable Biologics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Respiratory Inhalable Biologics Sales (k units ) of Manufacturers (2021-2026)
- 3.3 Global Respiratory Inhalable Biologics Revenue of Manufacturers (2021-2026)
- 3.4 Global Respiratory Inhalable Biologics Average Price by Manufacturers (2021-2026)
- 3.5 Global Respiratory Inhalable Biologics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Respiratory Inhalable Biologics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Respiratory Inhalable Biologics, Product Type & Application
- 3.8 Global Manufacturers of Respiratory Inhalable Biologics, Established Date
- 3.9 Global Respiratory Inhalable Biologics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Respiratory Inhalable Biologics Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 AstraZeneca
- 4.2.1 AstraZeneca Company Information
- 4.2.2 AstraZeneca Business Overview
- 4.2.3 AstraZeneca Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AstraZeneca Respiratory Inhalable Biologics Product Portfolio
- 4.2.5 AstraZeneca Recent Developments
- 4.3 Boehringer Ingelheim
- 4.3.1 Boehringer Ingelheim Company Information
- 4.3.2 Boehringer Ingelheim Business Overview
- 4.3.3 Boehringer Ingelheim Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Boehringer Ingelheim Respiratory Inhalable Biologics Product Portfolio
- 4.3.5 Boehringer Ingelheim Recent Developments
- 4.4 Vertex
- 4.4.1 Vertex Company Information
- 4.4.2 Vertex Business Overview
- 4.4.3 Vertex Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Vertex Respiratory Inhalable Biologics Product Portfolio
- 4.4.5 Vertex Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche Respiratory Inhalable Biologics Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Respiratory Inhalable Biologics Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Chiesi
- 4.7.1 Chiesi Company Information
- 4.7.2 Chiesi Business Overview
- 4.7.3 Chiesi Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Chiesi Respiratory Inhalable Biologics Product Portfolio
- 4.7.5 Chiesi Recent Developments
- 4.8 Teva
- 4.8.1 Teva Company Information
- 4.8.2 Teva Business Overview
- 4.8.3 Teva Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva Respiratory Inhalable Biologics Product Portfolio
- 4.8.5 Teva Recent Developments
- 4.9 Prasco Laboratories
- 4.9.1 Prasco Laboratories Company Information
- 4.9.2 Prasco Laboratories Business Overview
- 4.9.3 Prasco Laboratories Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Prasco Laboratories Respiratory Inhalable Biologics Product Portfolio
- 4.9.5 Prasco Laboratories Recent Developments
- 4.10 Viatris
- 4.10.1 Viatris Company Information
- 4.10.2 Viatris Business Overview
- 4.10.3 Viatris Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Viatris Respiratory Inhalable Biologics Product Portfolio
- 4.10.5 Viatris Recent Developments
- 4.11 Amgen
- 4.11.1 Amgen Company Information
- 4.11.2 Amgen Business Overview
- 4.11.3 Amgen Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Amgen Respiratory Inhalable Biologics Product Portfolio
- 4.11.5 Amgen Recent Developments
- 4.12 Sumitomo Dainippon
- 4.12.1 Sumitomo Dainippon Company Information
- 4.12.2 Sumitomo Dainippon Business Overview
- 4.12.3 Sumitomo Dainippon Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sumitomo Dainippon Respiratory Inhalable Biologics Product Portfolio
- 4.12.5 Sumitomo Dainippon Recent Developments
- 4.13 Zhengdatianqing
- 4.13.1 Zhengdatianqing Company Information
- 4.13.2 Zhengdatianqing Business Overview
- 4.13.3 Zhengdatianqing Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Zhengdatianqing Respiratory Inhalable Biologics Product Portfolio
- 4.13.5 Zhengdatianqing Recent Developments
- 4.14 Merck
- 4.14.1 Merck Company Information
- 4.14.2 Merck Business Overview
- 4.14.3 Merck Respiratory Inhalable Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Merck Respiratory Inhalable Biologics Product Portfolio
- 4.14.5 Merck Recent Developments
5 Global Respiratory Inhalable Biologics Market Scenario by Region
- 5.1 Global Respiratory Inhalable Biologics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Respiratory Inhalable Biologics Sales by Region: 2021-2032
- 5.2.1 Global Respiratory Inhalable Biologics Sales by Region: 2021-2026
- 5.2.2 Global Respiratory Inhalable Biologics Sales by Region: 2027-2032
- 5.3 Global Respiratory Inhalable Biologics Revenue by Region: 2021-2032
- 5.3.1 Global Respiratory Inhalable Biologics Revenue by Region: 2021-2026
- 5.3.2 Global Respiratory Inhalable Biologics Revenue by Region: 2027-2032
- 5.4 North America Respiratory Inhalable Biologics Market Facts & Figures by Country
- 5.4.1 North America Respiratory Inhalable Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Respiratory Inhalable Biologics Sales by Country (2021-2032)
- 5.4.3 North America Respiratory Inhalable Biologics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Respiratory Inhalable Biologics Market Facts & Figures by Country
- 5.5.1 Europe Respiratory Inhalable Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Respiratory Inhalable Biologics Sales by Country (2021-2032)
- 5.5.3 Europe Respiratory Inhalable Biologics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Respiratory Inhalable Biologics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Respiratory Inhalable Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Respiratory Inhalable Biologics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Respiratory Inhalable Biologics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Respiratory Inhalable Biologics Market Facts & Figures by Country
- 5.7.1 South America Respiratory Inhalable Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Respiratory Inhalable Biologics Sales by Country (2021-2032)
- 5.7.3 South America Respiratory Inhalable Biologics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Respiratory Inhalable Biologics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Respiratory Inhalable Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Respiratory Inhalable Biologics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Respiratory Inhalable Biologics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Respiratory Inhalable Biologics Sales by Type (2021-2032)
- 6.1.1 Global Respiratory Inhalable Biologics Sales by Type (2021-2032) & (k units )
- 6.1.2 Global Respiratory Inhalable Biologics Sales Market Share by Type (2021-2032)
- 6.2 Global Respiratory Inhalable Biologics Revenue by Type (2021-2032)
- 6.2.1 Global Respiratory Inhalable Biologics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Respiratory Inhalable Biologics Revenue Market Share by Type (2021-2032)
- 6.3 Global Respiratory Inhalable Biologics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Respiratory Inhalable Biologics Sales by Application (2021-2032)
- 7.1.1 Global Respiratory Inhalable Biologics Sales by Application (2021-2032) & (k units )
- 7.1.2 Global Respiratory Inhalable Biologics Sales Market Share by Application (2021-2032)
- 7.2 Global Respiratory Inhalable Biologics Revenue by Application (2021-2032)
- 7.2.1 Global Respiratory Inhalable Biologics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Respiratory Inhalable Biologics Revenue Market Share by Application (2021-2032)
- 7.3 Global Respiratory Inhalable Biologics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Respiratory Inhalable Biologics Value Chain Analysis
- 8.1.1 Respiratory Inhalable Biologics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Respiratory Inhalable Biologics Production Mode & Process
- 8.2 Respiratory Inhalable Biologics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Respiratory Inhalable Biologics Distributors
- 8.2.3 Respiratory Inhalable Biologics Customers
9 Global Respiratory Inhalable Biologics Analyzing Market Dynamics
- 9.1 Respiratory Inhalable Biologics Industry Trends
- 9.2 Respiratory Inhalable Biologics Industry Drivers
- 9.3 Respiratory Inhalable Biologics Industry Opportunities and Challenges
- 9.4 Respiratory Inhalable Biologics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst